Business context and reporting period
Donaldson Company, Inc. (NYSE: DCI) designs and sells filtration products and solutions across Mobile Solutions, Industrial Solutions and Life Sciences. This unaudited Form 10-Q covers the fiscal second quarter and first six months ended January 31, 2024; comparisons are with the corresponding 2023 periods unless noted.
Financial performance
| Metric | Q2 FY2024 | Q2 FY2023 | Six months FY2024 | Six months FY2023 |
|---|---|---|---|---|
| Net sales | $876.7 million | $828.3 million | $1,723.0 million | $1,675.6 million |
| Gross margin | 35.2% | 34.3% | 35.4% | 34.1% |
| Operating income | $129.7 million | $116.3 million | $254.3 million | $235.6 million |
| Net earnings | $98.7 million | $86.0 million | $190.8 million | $173.2 million |
| Diluted EPS | $0.81 | $0.70 | $1.56 | $1.40 |
| Operating cash flow | Not separately provided | Not separately provided | $225.0 million | $220.5 million |
Q2 sales rose 5.8%, net earnings rose 14.8% and diluted EPS rose 15.9%. For the six-month period, sales increased 2.8%, net earnings 10.2% and diluted EPS 11.4%. Management attributed sales growth to pricing and volume, with a favorable currency contribution year to date. Gross-margin improvement reflected pricing and lower freight and select material costs. Derived operating cash flow less capital expenditures was $180.5 million for the six months, compared with $162.9 million in the prior-year period.
Segment results
- Mobile Solutions: Q2 sales increased 5.3% to $550.3 million; segment earnings before tax were $99.2 million versus $78.6 million. Aftermarket growth, pricing and favorable mix helped; Off-Road sales declined amid weak agriculture conditions.
- Industrial Solutions: Q2 sales increased 6.9% to $263.4 million; earnings before tax were $47.4 million versus $46.3 million. Higher volume in industrial filtration and strength in defense were partly offset by unfavorable mix.
- Life Sciences: Q2 sales increased 6.0% to $63.0 million, but the segment recorded a $5.8 million pretax loss versus $6.3 million pretax earnings. Management cited planned investment to scale recently acquired businesses. The six-month pretax loss was $10.0 million.
Financial position and liquidity
- At January 31, 2024, cash and cash equivalents were $193.8 million, versus $187.1 million at July 31, 2023. Current assets were $1,317.2 million and current liabilities $893.5 million.
- Balance-sheet debt, including short-term borrowings and current maturities, totaled $614.1 million at January 31, 2024, compared with $655.7 million at July 31, 2023. Debt was 30.9% of total capitalization, down from 33.2%.
- The company reported $642.2 million of borrowing capacity under existing credit facilities, including $452.5 million available on its $500 million revolving facility, which expires May 21, 2026. It was in compliance with debt covenants and said available liquidity should meet requirements for the next 12 months and beyond.
- Six-month investing cash outflow was $44.5 million, principally capital expenditures. Financing cash outflow was $171.7 million, including $86.6 million of treasury-stock purchases and $60.3 million of dividends paid.
Changes, outlook and risks
- Sales growth was broad in Q2, while year-to-date growth was led by Industrial Solutions. Mobile Aftermarket gains were offset in part by weaker Off-Road demand. Life Sciences profitability deteriorated as the company invested in acquired businesses.
- Interest expense increased 20.3% in Q2 and 20.5% year to date, which management attributed to higher variable interest rates. Other income increased, primarily from higher joint-venture earnings and lower foreign-currency losses.
- No specific numerical earnings or sales guidance is provided in the supplied filing text. Management described liquidity as sufficient for anticipated needs, including investment, dividends, repurchases and potential acquisitions.
- Key stated risks include global economic, industrial and political conditions; demand fluctuations and cyclical end markets; raw-material availability and cost inflation; competition and pricing pressure; foreign-currency and interest-rate movements; acquisition execution; workforce and cybersecurity risks; and regulatory requirements.
- Claims and litigation provisions were not material, and the company considered material amounts beyond recorded accruals remote for currently identified matters. Unrecognized tax benefits were $15.8 million, with $2.2 million of accrued interest and penalties; potential audit outcomes could still change reserves.
- The company guarantees half of certain AFSI joint-venture debt; AFSI debt was $55.4 million, making Donaldson’s guaranteed share approximately half. Purilogics acquisition-related contingent consideration was $24.3 million, with a maximum payout of $29.0 million.
- No material restructuring charges were recorded in the current six-month period. Prior-year results included organizational redesign and customer-program exit charges. UTEC acquisition purchase accounting remained preliminary; its sales contribution was described as immaterial.
Important facts for investors to verify
- Whether Life Sciences investments produce improved sales and segment profitability, and the pace of integration and scaling of acquired businesses.
- Whether Mobile Solutions’ Aftermarket strength can offset continued weakness in Off-Road demand, and whether Industrial Solutions can sustain growth without margin pressure from product mix.
- Debt maturities, variable-rate exposure and available facility capacity; the balance sheet reports $211.7 million of current maturities, while the revolving facility has $452.5 million available.
- Cash conversion and working capital: inventory increased to $433.4 million, while days inventory on hand rose to 70 from 69 at fiscal year-end.
- Potential changes in acquisition-related contingent consideration, tax reserves, and the final UTEC purchase-price allocation.